Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Caroline Dartigeas

Real-World Results of Ibrutinib in Relapsed/Refractory CLL in France: Early Results on a Large Series of 428 Patients

American Journal of Hematology
Hematology
2017English

Bendamustine Plus Rituximab in Newly‐diagnosed Waldenström Macroglobulinaemia Patients. A Study on Behalf of the French Innovative Leukaemia Organization (FILO)

British Journal of Haematology
Hematology
2018English

Related publications

Cost-Effectiveness of Ibrutinib in Patients With Relapsed or Refractory (RR) Chronic Lymphocytic Leukaemia (CLL) in England

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2017English

Ibrutinib for Relapsed / Refractory Cll: An Update of the Uk and Ireland Analysis of Outcomes in 315 Patients

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2017English

Results of an Early Access Treatment Protocol of Daratumumab in United States Patients With Relapsed or Refractory Multiple Myeloma

Cancer
Cancer ResearchOncology
2018English

Results From the Safety Run-In Period of the Sympatico Study Evaluating Ibrutinib in Combination With Venetoclax in Patients With Relapsed/Refractory Mantle Cell Lymphoma

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Real-World Bendamustine Use in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R Dlbcl)

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Ibrutinib as Treatment for Patients With Relapsed/Refractory Follicular Lymphoma: Results From the Open-Label, Multicenter, Phase II DAWN Study

Journal of Clinical Oncology
Cancer ResearchMedicineOncology
2018English

Interim Results of OPAL, a Study of Tosedostat in Elderly Relapsed/Refractory AML.

Journal of Clinical Oncology
Cancer ResearchMedicineOncology
2011English

Preliminary Results of Earlier Steroid Use With Axicabtagene Ciloleucel (Axi-Cel) in Patients With Relapsed/Refractory Large B Cell Lymphoma

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Phase 2 Study of Acalabrutinib in Ibrutinib-Intolerant Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy